BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37079318)

  • 1. Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis.
    Baboudjian M; Gondran-Tellier B; Dariane C; Fiard G; Fromont G; Rouprêt M; Ploussard G
    JAMA Oncol; 2023 Jun; 9(6):847-850. PubMed ID: 37079318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
    Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
    JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
    Hong SK; Oh JJ; Lee S; Lee HM; Byun SS; Choe G; Lee SE
    Prostate; 2012 Aug; 72(11):1187-92. PubMed ID: 22161951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
    An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
    JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between beta-blockers use and prostate cancer mortality: A mini systematic review and meta-analysis.
    Uleri A; Baboudjian M; Tedde A; Rajwa P; Pradere B; Gallioli A; Breda A; Ploussard G
    Prostate; 2024 Jan; 84(1):3-7. PubMed ID: 37710384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis.
    Luo LM; Yang RD; Wang JM; Zhao SK; Liu YZ; Zhu ZG; Xiang Q; Zhao ZG
    Asian J Androl; 2020; 22(5):532-538. PubMed ID: 31710001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer specific mortality after 5α-reductase inhibitors medication in benign prostatic hyperplasia patients: systematic review and meta-analysis.
    Park JJ; Lee HY; Shim SR; Lee SW; Kim KT; Kim JH
    Aging Male; 2021 Dec; 24(1):80-91. PubMed ID: 34889709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
    Azoulay L; Eberg M; Benayoun S; Pollak M
    JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
    Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
    J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
    Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
    J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of 5-alpha-reductase inhibitors on mortality in a prostate cancer chemoprevention setting: a meta-analysis.
    Knijnik PG; Brum PW; Cachoeira ET; Paludo AO; Gorgen ARH; Burttet LM; Neyeloff JL; Neto BS
    World J Urol; 2021 Feb; 39(2):365-376. PubMed ID: 32314009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis.
    Elwenspoek MMC; Sheppard AL; McInnes MDF; Merriel SWD; Rowe EWJ; Bryant RJ; Donovan JL; Whiting P
    JAMA Netw Open; 2019 Aug; 2(8):e198427. PubMed ID: 31390032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis.
    Foerster B; Pozo C; Abufaraj M; Mari A; Kimura S; D'Andrea D; John H; Shariat SF
    JAMA Oncol; 2018 Jul; 4(7):953-961. PubMed ID: 29800115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.
    Campi R; Brookman-May SD; Subiela Henríquez JD; Akdoğan B; Brausi M; Klatte T; Langenhuijsen JF; Linares-Espinos E; Marszalek M; Roupret M; Stief CG; Volpe A; Minervini A; Rodriguez-Faba O
    Eur Urol Focus; 2019 Nov; 5(6):1029-1057. PubMed ID: 29661588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.